OpenBit ResearchOpenBit
中文

What's driving Roivant Sciences (ROIV)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Can IMVT-1402 demonstrate a viable cutaneous lupus treatment effect?

Why it matters now

The cutaneous lupus development outcome affects the value assigned to ROIV's IMVT-1402 program; favorable safety and directional efficacy evidence provide offsetting support while the failed primary endpoint weighs against the program.

Next checkpoint

ROIV earnings (expected 2026-11-09)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to ROIV, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

The mechanism is invalidated for this indication if the program remains unable to meet the primary endpoint or development bar.

Research drivers

  • Can IMVT-1402 demonstrate a viable cutaneous lupus treatment effect?

    Mixed · Cooling · Updated

    The available study evidence does not support continued IMVT-1402 development in cutaneous lupus despite favorable safety and positive trends on multiple endpoints.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • IMVT-1402 demonstrated a favorable safety and tolerability profile consistent with prior studies.

    Relayed by: Benzinga · Event date on record:

  • Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes.

    Relayed by: Benzinga · Event date on record:

  • The study did not meet Immunovant’s internal bar to continue development of IMVT-1402 in cutaneous lupus erythematosus.

    Relayed by: Benzinga · Event date on record:

  • Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus did not achieve statistical significance on the primary endpoint of CLASI-A percent change from baseline at Week 12.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.